Skip to content

Study · Non-randomized trial · n = 40 · 1999

8 results

Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.

Gobburu JV, Agersø H, Jusko WJ, Ynddal L

Pharmaceutical research1 Sept 1999Cited by 17 (Europe PMC)

PMID10496658 (opens in a new tab)DOI10.1023/a:1018955126402 (opens in a new tab)PepBankPUB-10496658
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanNon-randomized trialPharmacokinetics

    In healthy male volunteers, the pharmacokinetic parameters of ipamorelin showed dose-proportionality across the tested infusion doses.

    In plain wordsIn healthy men, the body's handling of ipamorelin rose in proportion to the dose.

    Peptide
    Ipamorelin
    Outcome
    Not applicableDose proportionality of ipamorelin pharmacokinetics
    Study

    n = 40

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg · 15 minutes infusionAs given in this study (human).

    Source sentences

    Summary
    The PK parameters showed dose-proportionality
    2 context sentences
    Summary · context
    To examine the pharmacokinetics (PK) and pharmacodynamics (PD) of ipamorelin, a growth hormone (GH) releasing peptide, in healthy volunteers.
    Summary · context
    A trial was conducted with a dose escalation design comprising 5 different infusion rates (4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutes) with eight healthy male subjects at each dose level.
  2. 02HumanNon-randomized trialPharmacokinetics

    In healthy male volunteers, ipamorelin had a short terminal half-life of 2 hours.

    In plain wordsIn healthy men, ipamorelin had a short terminal half-life of about 2 hours.

    Peptide
    Ipamorelin
    Outcome
    Not applicableTerminal half-life
    Study

    n = 40

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg · 15 minutes infusionAs given in this study (human).

    Measurements

    Terminal half-life
    2 hours
    healthy male volunteers

    Source sentences

    Summary
    a short terminal half-life of 2 hours
    2 context sentences
    Summary · context
    To examine the pharmacokinetics (PK) and pharmacodynamics (PD) of ipamorelin, a growth hormone (GH) releasing peptide, in healthy volunteers.
    Summary · context
    A trial was conducted with a dose escalation design comprising 5 different infusion rates (4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutes) with eight healthy male subjects at each dose level.
  3. 03HumanNon-randomized trialPharmacokinetics

    In healthy male volunteers, the clearance of ipamorelin was 0.078 L/h/kg.

    In plain wordsIn healthy men, the body cleared ipamorelin at 0.078 litres per hour per kilogram.

    Peptide
    Ipamorelin
    Outcome
    Not applicableClearance
    Study

    n = 40

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg · 15 minutes infusionAs given in this study (human).

    Measurements

    Clearance
    0.078 L/h/kg
    healthy male volunteers

    Source sentences

    Summary
    a clearance of 0.078 L/h/kg
    2 context sentences
    Summary · context
    To examine the pharmacokinetics (PK) and pharmacodynamics (PD) of ipamorelin, a growth hormone (GH) releasing peptide, in healthy volunteers.
    Summary · context
    A trial was conducted with a dose escalation design comprising 5 different infusion rates (4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutes) with eight healthy male subjects at each dose level.
  4. 04HumanNon-randomized trialPharmacokinetics

    In healthy male volunteers, the volume of distribution of ipamorelin at steady-state was 0.22 L/kg.

    In plain wordsIn healthy men, ipamorelin spread through a volume of 0.22 litres per kilogram of body weight.

    Peptide
    Ipamorelin
    Outcome
    Not applicableVolume of distribution at steady-state
    Study

    n = 40

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg · 15 minutes infusionAs given in this study (human).

    Measurements

    Volume of distribution at steady-state
    0.22 L/kg
    healthy male volunteers

    Source sentences

    Summary
    a volume of distribution at steady-state of 0.22 L/kg.
    2 context sentences
    Summary · context
    To examine the pharmacokinetics (PK) and pharmacodynamics (PD) of ipamorelin, a growth hormone (GH) releasing peptide, in healthy volunteers.
    Summary · context
    A trial was conducted with a dose escalation design comprising 5 different infusion rates (4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutes) with eight healthy male subjects at each dose level.
  5. 05HumanNon-randomized trialEfficacy outcome

    In healthy male volunteers, ipamorelin stimulated a single episode of GH release that peaked at 0.67 hours and declined to negligible levels at all doses.

    In plain wordsIn healthy men, ipamorelin caused one pulse of growth hormone release that peaked within one hour.

    Peptide
    Ipamorelin
    Outcome
    IncreaseGH release time course after ipamorelin
    Study

    n = 40

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg · 15 minutes infusionAs given in this study (human).

    Measurements

    Time of peak GH
    0.67 hours
    all doses

    Source sentences

    Summary
    The time course of GH stimulation by ipamorelin showed a single episode of GH release with a peak at 0.67 hours and an exponential decline to negligible GH concentration at all doses.
    2 context sentences
    Summary · context
    To examine the pharmacokinetics (PK) and pharmacodynamics (PD) of ipamorelin, a growth hormone (GH) releasing peptide, in healthy volunteers.
    Summary · context
    A trial was conducted with a dose escalation design comprising 5 different infusion rates (4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutes) with eight healthy male subjects at each dose level.
  6. 06HumanNon-randomized trialActivity measurement

    In healthy male volunteers, ipamorelin induced GH release at all dose levels, with an SC50 for half-maximal GH stimulation of 214 nmol/L.

    In plain wordsIn healthy men, ipamorelin released growth hormone at every dose. Half of the maximal effect needed 214 nanomoles per litre.

    Peptide
    Ipamorelin
    Outcome
    IncreaseSC50 for GH stimulation
    Study

    n = 40

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg · 15 minutes infusionAs given in this study (human).

    Measurements

    SC50
    214 nmol/L
    GH stimulation, healthy male volunteers

    Source sentences

    Summary
    Ipamorelin induces the release of GH at all dose levels with the concentration (SC50) required for half-maximal GH stimulation of 214 nmol/L
    2 context sentences
    Summary · context
    To examine the pharmacokinetics (PK) and pharmacodynamics (PD) of ipamorelin, a growth hormone (GH) releasing peptide, in healthy volunteers.
    Summary · context
    A trial was conducted with a dose escalation design comprising 5 different infusion rates (4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutes) with eight healthy male subjects at each dose level.
  7. 07HumanNon-randomized trialActivity measurement

    In healthy male volunteers, the maximal GH production rate with ipamorelin was 694 mIU/L/h.

    In plain wordsIn healthy men, the highest rate of growth hormone production caused by ipamorelin was 694 mIU/L/h.

    Peptide
    Ipamorelin
    Outcome
    IncreaseMaximal GH production rate
    Study

    n = 40

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg · 15 minutes infusionAs given in this study (human).

    Measurements

    Maximal GH production rate
    694 mIU/L/h
    healthy male volunteers

    Source sentences

    Summary
    and a maximal GH production rate of 694 mIU/L/h.
    2 context sentences
    Summary · context
    To examine the pharmacokinetics (PK) and pharmacodynamics (PD) of ipamorelin, a growth hormone (GH) releasing peptide, in healthy volunteers.
    Summary · context
    A trial was conducted with a dose escalation design comprising 5 different infusion rates (4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutes) with eight healthy male subjects at each dose level.
  8. 08HumanNon-randomized trialPharmacokinetics

    In healthy male volunteers, the inter-individual variability of the pharmacodynamic parameters was larger than that of the pharmacokinetic parameters.

    In plain wordsIn healthy men, people differed more in how they responded to ipamorelin than in how their bodies handled it.

    Peptide
    Ipamorelin
    Outcome
    Not applicableInter-individual variability of PD and PK parameters
    Study

    n = 40

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg · 15 minutes infusionAs given in this study (human).

    Source sentences

    Summary
    The inter-individual variability of the PD parameters was larger than that of the PK parameters.
    2 context sentences
    Summary · context
    To examine the pharmacokinetics (PK) and pharmacodynamics (PD) of ipamorelin, a growth hormone (GH) releasing peptide, in healthy volunteers.
    Summary · context
    A trial was conducted with a dose escalation design comprising 5 different infusion rates (4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutes) with eight healthy male subjects at each dose level.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.